$RLFTF (copy) Props to Alexandre below who linked a report
$RLFTF (copy) Props to Alexandre below who linked a report from Relief in 2016. It was very illustrative especially about their history and their focus up to that year. Not sure it has been thoroughly discussed, but here are some of the highlights if anyone is interested that I personally found interesting.
1. They did have a CEO and other typical C-level suite guys as late as that report in 2016. Will have to do some digging to find out what happened there (if someone knows please let me know).
2. They mentioned even then their opinion is to outsource as much as they can and keep the company as "lean" as possible. They found using CRO's to do the research stuff saved money AND published research showed that CRO were on time 30% more often then doing research with in house folks. So I was wrong that how they are not ramping up and getting bigger in preparation of building off aviptadil is a sign something is amiss in the company. It seems that approach (right or wrong) is within their philosophy even back in 2016.
3. They did a phase II using aviptadil for sacroidosis and seemed to start a phase III. Tried googling the name of the phase III, but found nothing about what happened to it. Anybody know?
4. Their phase II for sarcoidosis was very interesting. It was done using an INHALED version which showed no adverse effects. So this most likely points to the INHL trial we have set up for COVID going off with no adverse effects. The study seemed not to make a difference in lung volumes in sarcoidosis based on how the results showed no change in TLC (total lung capacity) which are decreased in that disease state being a restrictive lung disease. No change in other lung parameters or gas exchange. They should have measured pulmonary pressures and right heart pressures as well to see if their was an pulmonary vasodilation and thus decrease in right sided heart strain, but oh well we can't get everything.
5. The phase II for sarcoidosis DID show once again SIGNIFICANT (75%+) decrease in inflammation via decreased TNF-alpha. This confirms nearly EVERY study to date via IV and now inhaled version it decreases inflammatory mediators. I have NO CLUE why their team didn't notice this and change direction to start trialing this for inflammatory conditions, i.e. sepsis, Inflammatory bowel disease, rheum. disease (RA, SLE, etc...).
As I have stated from the beginning this is BY FAR the most interesting aspect of this drug. It may be the "holy grail" of inflammation WITH no significant side effects via an easy route of administration (inhaled).
6. They made an agreement to offer to license aviptadil to a small, private biotech company for them to do the trials for INHL aviptadil for sarcoidosis and acute lung injury. The latter I am wondering if it went though will affect any revenue going forward for indications like that which is a precursor to ARDS by definition.
In that agreement they stated in 2018 it may also be for the RIGHTS to the patent for those indications if certain goals are met. I am assuming nothing materialized out of that agreement, but does anyone have an DD on that matter?
Maybe some of our European friends who have known the company and the biotech space in Europe will be able to flesh this part of the story out for us?
Either way that was a very interesting read on a company BEFORE they gained instant fame now due to COVID and their hopeful treatment.
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼
Top 10 Most Recent News Articles
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...
Continue Reading
Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...
Continue Reading
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...
Continue Reading
Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...
Continue Reading
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...
Continue Reading
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue Reading
Top 5 Most Recently Viewed Articles
Exploring Leadership in a Changing Workplace The recent episode of Info-Tech Research Group's podcast, Digital Disruption, highlights a thought-provoking discussion with bestselling author Daniel Pink, focusing on how leaders can adapt in a time he describes as 'the great sort'. This term encapsulates the ongoing transformation in our approach to work, leadership, and the...
Continue Reading
MORSE Corp's Commitment to Community Service MORSE Corp recently dedicated an entire day to community service by hosting a cleanup initiative at local beaches and parks. On a beautiful Wednesday, the organization mobilized its team to gather at a coastal spot to improve the environment and promote community spirit. This initiative is part of their annual effort to...
Continue Reading
Revolutionizing Nutrition Transparency for Consumers Today, the U.S. Food and Drug Administration (FDA) is taking significant steps towards improving consumer awareness about the nutritional value of packaged foods. A new proposal dictates that most packaged foods will require a prominent front-of-package (FOP) nutrition label. This initiative is part of a broader...
Continue Reading
CW Bancorp Announces Dividend Declaration CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, has approved a quarterly cash dividend. The news comes as the company continues to prioritize shareholder value while supporting its growth journey. Details of the Cash Dividend The Board of Directors of CW Bancorp declared a cash dividend of $0.23 per common...
Continue Reading
Universal Electronics Introduces QuickSet homeSense Technology Universal Electronics Inc. (NASDAQ: UEIC) has made headlines by launching its innovative QuickSet homeSense technology. This introduction took place at the prestigious International Consumer Electronics Show (CES) where the spotlight is often on groundbreaking tech. UEI, a leader in wireless control solutions,...
Continue Reading